Based on these compelling findings, lorlatinib was identified as a potentially effective treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) while exhibiting an expected safety profile during phase I and phase II trials [19]. This evidence concerns the gene ALK and non-small cell lung carcinoma.